[go: up one dir, main page]

WO2023232215A1 - Composition pharmaceutique améliorée contenant du tadalafil et son procédé de préparation - Google Patents

Composition pharmaceutique améliorée contenant du tadalafil et son procédé de préparation Download PDF

Info

Publication number
WO2023232215A1
WO2023232215A1 PCT/EP2022/000051 EP2022000051W WO2023232215A1 WO 2023232215 A1 WO2023232215 A1 WO 2023232215A1 EP 2022000051 W EP2022000051 W EP 2022000051W WO 2023232215 A1 WO2023232215 A1 WO 2023232215A1
Authority
WO
WIPO (PCT)
Prior art keywords
agents
active ingredient
tadalafil
sieve
pharmaceutical composition
Prior art date
Application number
PCT/EP2022/000051
Other languages
English (en)
Inventor
Agni GRYPIOTI
George Papandreou
Panagiotis TSITSAS
Original Assignee
Rontis Hellas S.A.
Pharos Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rontis Hellas S.A., Pharos Ltd. filed Critical Rontis Hellas S.A.
Priority to PCT/EP2022/000051 priority Critical patent/WO2023232215A1/fr
Publication of WO2023232215A1 publication Critical patent/WO2023232215A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Definitions

  • the present invention relates to an improved pharmaceutical composition for oral administration, and in particular to a chewable pharmaceutical composition comprising a therapeutically effective quantity of tadalafil or a pharmaceutically acceptable salt or derivative thereof, as an active ingredient, and an effective quantity of a non-ionic water dispersible surfactant as solubilizing agent in order to improve the solubility, bioavailability and onset of action of said active ingredient. Furthermore, the present invention relates to a process for the preparation of said pharmaceutical composition.
  • Erectile dysfunction can have a range of causes, both physical and psychological. Possible physical causes include heart disease, diabetes, high blood pressure (hypertension) and hormonal problems. Possible psychological causes include stress, anxiety, depression, and relationship problems. ED is treatable at any age, and awareness of this fact has been growing.
  • Oral phosphodiesterase-5 inhibitors (PDE-5 inhibitors) have become the preferred first-line treatment for erectile dysfunction worldwide.
  • PDE-5 inhibitors are competitive inhibitors of phosphodiesterase type 5 (PDE-5), an enzyme that breaks down cyclic guanosine monophosphate (cGMP) in various tissues, the second messenger of Nitric Oxide (NO). By inhibiting cGMP breakdown, PDE-5 inhibitors enhance the vasodilatory effect of NO and restore the ability to achieve an erection in patients with erectile dysfunction.
  • Tadalafil is a potent and selective PDE-5 inhibitor, a secondary messenger for the smooth muscle relaxing effects of NO, which plays an important role in the vasodilation of erectile tissues.
  • Tadalafil has the IUPAC name of pyrazino[l',2':l,6]pyrido[3,4-b]indole-l, 4-dione, _6-(l,3- benzodioxol-5-yl)-2,3,6,7,12,12a- hexahydro-2-methyl-, (6R,12aR). It is a crystalline solid, practically insoluble in water and very slightly soluble in ethanol.
  • Tadalafil is commercially available under the brand name Cialis® (a film-coated, almond-shaped tablet for oral administration). Each tablet contains 2.5, 5, 10, or 20 mg of Tadalafil and the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, hypromellose, iron oxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, talc, titanium dioxide, and triacetin.
  • Cialis® a film-coated, almond-shaped tablet for oral administration.
  • Each tablet contains 2.5, 5, 10, or 20 mg of Tadalafil and the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, hypromellose, iron oxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, talc, titanium dioxide, and triacetin.
  • Tadalafil is well absorbed after oral administration with a mean maximum observed plasma concentration (Cmax) of 378 ng/mL after oral administration of the 20-mg tablet. Cmax is achieved at a mean time of 2 hours after dosing. Tadalafil mean volume of distribution is approximately 63 L, with a mean half-life of 17.5 hours in healthy subjects.
  • aqueous solubility of an active ingredient is one of the most important physicochemical properties as low aqueous solubility and low dissolution rate can reduce the active ingredient absorption in the gastro-intestinal tract.
  • Low active ingredient solubility also directs to decreased bioavailability, increased chance of food effect, more frequent incomplete release from the dosage form and higher interpatient variability.
  • Poorly water soluble active ingredients consist a large majority of the pharmaceutical active ingredients, thereby limiting their potential uses and increasing the difficulty of formulating bioavailable pharmaceutical products.
  • Poorly soluble active ingredients have stimulated the development of active ingredient delivery technologies to overcome the obstacles to their solubilization through either chemical or mechanical modification of the environment surrounding the active ingredient molecule, or physically altering the macromolecular characteristics of aggregated active ingredient particles.
  • These technologies include both traditional methods of solubility enhancement, such as particle size reduction, addition of surfactants and inclusion in cyclodextrin-active ingredient complexes, and the use of more novel mechanisms such as self-emulsifying systems, micronisation via nanoparticles, pH adjustment and salting-in processes.
  • EP-B-0828479 relates to a solid dispersion comprising Tadalafil and a carrier or excipient thereof and a manufacturing process comprising the co-precipitating of the poorly water soluble drug and the carrier or excipient.
  • EP-A- 1200090 refers to a pharmaceutical formulation comprising Tadalafil in “free drug” (not intimately embedded in a polymeric co-precipitate) form in a mixture with a diluent, lubricant, a hydrophilic binder, and a disintegrant.
  • EP-B- 1200092 claims a pharmaceutical composition
  • a pharmaceutical composition comprising a free drug form of Tadalafil, salts and solvates thereof and at least one carrier, diluent or excipient, in which the compound is present as solid particles not intimately embedded in a polymeric co-precipitate and wherein at least 90 % of the particles have a particle size of ⁇ 40 microns
  • an object of the present invention to provide an improved solid pharmaceutical composition for oral administration comprising Tadalafil as an active ingredient, which is bioavailable, with sufficient shelf-life and good pharmacotechnical properties.
  • Another aspect of the present invention is to achieve a solid immediate release formulation for oral administration comprising Tadalafil as an active ingredient, with improved solubility and bioavailability characteristics which further may exhibits a faster therapeutic onset compared to the commercially available product Cialis® (reference product).
  • a further aspect of the present invention is to afford a method for the preparation of a solid pharmaceutical composition for oral administration which overcomes the difficulties encountered in pharmaceutical production because of the low solubility of Tadalafil.
  • a pharmaceutical composition for oral administration, preferable chewable pharmaceutical composition comprising a therapeutically effective quantity of Tadalafil or a pharmaceutically acceptable salt or derivative thereof, as an active ingredient and an effective quantity of a non-ionic water dispersible surfactant as a solubilizing agent in order to improve the solubility, bioavailability and onset of action of the active ingredient in the finished dosage form.
  • a process for the preparation of a pharmaceutical dosage form for oral administration comprising a therapeutically effective quantity of Tadalafil or a pharmaceutically acceptable salt or derivative thereof as an active ingredient, and an effective quantity of a non-ionic water dispersible surfactant as a solubilizing agent in order to improve the solubility, bioavailability and onset of action of the active ingredient in the finished dosage form, is provided, wherein said process comprises the following steps:
  • Dispensing of active ingredient Weight individually the active ingredient (Tadalafil) and sieve through appropriate sieve.
  • Dispensing and sieving of intra-granular excipients Weight and mix diluents Lactose Monohydrate and Microcrystalline Cellulose and sieve through appropriate sieve. 5. Loading: Add the intra-granular excipients in a high shear mixer granulator and load the active ingredient dispersion in molten liquid mixture of Lauroyl macrogol-32 glycerides from step 3 on the intra-granular excipients, and mix until a homogenized waxy mixture is obtained and allow granules to cool down.
  • Compression Compress the homogeneous powder obtained from step 9 in tablets in a rotary tabletting machine using appropriate punches.
  • Fig. 1 Comparative dissolution profiles of composition 3 of the present invention comprising a solubilizing agent and composition 3a that does not comprise any solubilizing agent.
  • Fig. 2 Comparative dissolution profiles of the pharmaceutical composition 3 of the present invention and reference product at 50 rpm in water containing a surfactant to provide sink condition.
  • Fig. 3 Comparative dissolution profiles of the pharmaceutical composition 3 of the present invention and reference product at 50 rpm and under FED conditions.
  • a pharmaceutical composition comprising an active ingredient (Tadalafil) is considered to be improved if said composition achieves increased solubility, bioavailability and earlier therapeutically effective drug concentration than the known pharmaceutical formulations of Tadalafil.
  • a major object of the present invention is to provide a solid immediate release formulation of Tadalafil which is simple to manufacture, cost effective, posses good pharmacotechnical properties and linearity.
  • Another aspect of the present invention is to provide an immediate release formulation of Tadalafil in the form of a chewable tablet, which reaches the minimum effective drug concentration in plasma in a shorter period than the commercially available product Cialis® (hereafter referred to as reference product).
  • the object of the present invention is achieved by employing a novel technological platform such as melt granulation process combined with a non-ionic water dispersible surfactant, as a solubilizing agent, such as Lauroyl macrogol-32 glycerides mixture.
  • a novel technological platform such as melt granulation process combined with a non-ionic water dispersible surfactant, as a solubilizing agent, such as Lauroyl macrogol-32 glycerides mixture.
  • the active ingredient is suspended in a molten liquid solution comprised of Lauroyl macrogol-32 glycerides mixture and subsequently loaded on intra-granular excipients.
  • the granules pass through appropriate sieve, mixed with extra granular excipients and lubricant.
  • the mixture is compressed into tablets.
  • the water-miscible surfactant molecules containing both a hydrophobic and hydrophilic portion can solubilize many poorly water-soluble drugs which directly correlates to an increase in dissolution rate and bioavailability which is the greatest contribution to the object of the present invention.
  • melt granulation is a process by which pharmaceutical powders are efficiently agglomerated by the use of a binder which can be a molten liquid, a solid or a solid that melts during the process.
  • apparatus of choice are the high shear mixers, where the product temperature is raised above the melting point of the binder, by a heating jacket or, when the impeller speed is high enough, by the heat of friction generated by the impeller blades or even by melting the binder externally and preparing a suitable dispersion solution with the aim to be added in the high shear mixer.
  • Lauroyl macrogol-32 glycerides mixture is a well-characterized, safe excipient which conforms to the USP-NF and EP pharmacopoeias and is a waxy solid with low melting point and a suitable candidate for the process of melt granulation.
  • Lauroyl macrogol-32 glycerides is also a solubilizing agent, non-ionic water dispersible surfactant recommended for use in lipid-based formulations to increase the aqueous solubility and oral bioavailability of poorly water soluble drugs.
  • Water-miscible surfactant molecules contain both a hydrophobic and hydrophilic portion and can solubilize many poorly water-soluble drugs.
  • Surfactants can also self-assemble to form micelles once the surfactant monomer concentration reaches the critical micelle concentration. Thus, surfactants can solubilize drug molecules by either a direct cosolvent effect or by uptake into micelles.
  • compositions of the present invention may also contain one or more additional formulation ingredients selected from a wide variety of excipients. According to the desired properties of the composition, any number of ingredients may be selected, alone or in combination, based upon their known uses in preparation of solid dosage form compositions (tablet/capsule compositions).
  • Such ingredients include, but are not limited to, diluents, binders, compression aids, disintegrants, glidants, lubricants, flavors, water scavengers, colorants, sweetener, coating agents and preservatives.
  • the optional excipients must be compatible with Tadalafil or salt, metabolite or derivative thereof so that it does not interfere with it in the composition.
  • any excipient may optionally be added to the above composition, provided that they are compatible with the active ingredient of the composition, in order to overcome problems associated with unfavorable pharmacotechnical characteristics of these substances, and in order to increase the stability of the drug and the shelf-life of the pharmaceutical product, and provide a product exhibiting excellent bioavailability and palatability.
  • composition of the present invention may include further additives (alone or in a combination) such as absorbents, acids, adjuvants, anticaking agents, glidants, antitacking agents, antifoamers, anticoagulants, antimicrobials, antiseptics, diluents, binders, chelating agents, sequestrants, coating agents, colorants, dyes, pigments, complexing agents, softeners, ciystal growth regulators, denaturants, desiccants, dehydrating agents, dispersants, solubilizers, emollients, emulsifiers, fillers, flavor masking agents, gelling agents, humectants, lubricants, moisturizers, bufferants, pH control agents, plasticizers, retarding agents, stabilizers, suspending agents, sweeteners, disintegrants, thickening agents, surfactants, opacifiers, coloring agents, preservatives, antigellants, rheology control agents, tonicifiers
  • Diluents may be selected from calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulfate, microcrystalline cellulose, microcrystalline silicified cellulose, powdered cellulose, dextrates, dextrose, fructose, lactitol, lactose anhydrous, lactose monohydrate, lactose dihydrate, lactose trihydrate, mannitol, sorbitol, starch, pregelatinized starch, sucrose, talc, xylitol, maltose, isomalt, maltodextrin, maltitol and the like. Diluents may be in the range of 10-90 weight % of the total weight of the composition.
  • Binders may be selected from acacia, alginic acid, carbomer, carboxymethylcellulose calcium, carbomethylcellulose sodium, microcrystalline cellulose, powdered cellulose, ethyl cellulose, gelatin liquid glucose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, maltodextrin, methylcellulose, polydextrose, polyethylene oxide, , sodium alginate, starch paste, pregelatinized starch, sucrose, tragacanth, low-substituted hydroxypropyl cellulose, glucose, sorbitol. Binders may be in the range of 1-4’0 weight % of the total weight of the composition.
  • Disintegrants may be selected from alginic acid, carbon dioxide, carboxymethylcellulose calcium, carboxymethylcellulose sodium, microcrystalline cellulose, powdered cellulose, croscarmelose sodium, crospovidone, sodium docusate, gaur gum, hydroxypropyl cellulose, methylcellulose, polacrilin potassium, poloxamer, povidone, sodium alginate, sodium glycine carbonate, sodium laulyl sulfate (SLS), sodium starch glycolate, starch, pregelatinized starch, low-substituted hydroxypropyl cellulose and the like. Disintegrants may be in the range of 0.1 - 25 weight % of the total weight of the composition.
  • Glidants may be selected from calcium silicate, powdered cellulose, starch, talc, colloidal silicon dioxide and the like. Glidants may be in the range of 0.01-2 weight % of the total weight of the composition.
  • Lubricants may be selected from magnesium stearate, stearic acid, sodium stearyl fumarate, magnesium lauryl sulphate, talc, polyethylene glycol, glyceryl behenate and the like. Lubricants may be in the range of 0.01-2 weight % of the total weight of the composition.
  • Suitable sweeteners may be selected from sugars such as sucrose, lactose and glucose; cyclamate and salts thereof; saccharin and salts thereof; aspartame and the like.
  • Flavouring agents may be selected from natural or synthetic flavours such as strawberry flavour, wild cherry flavour, green apple flavour, spearmint flavor, peppermint flavor and the like.
  • Solubilizers may be selected from sodium lauryl sulphate or complex forming agents such as cyclodextrins, ion exchange resins, crown ethers and mixture of Polyoxylglyceride and the like.
  • the manufacturing process used for the preparation of a pharmaceutical dosage form for oral administration comprising a therapeutically effective quantity of Tadalafil or a pharmaceutically acceptable salt or derivative thereof as an active ingredient, and an effective quantity of a non-ionic water dispersible surfactant as a solubilizing agent in order to enhance the solubility, bioavailability and onset of action of the active ingredient in the finished dosage form, comprises the following steps:
  • Dispensing of active ingredient Weight individually the active ingredient (Tadalafil) and sieve through appropriate sieve.
  • Dispensing and sieving of intra-granular excipients Weight and mix Lactose Monohydrate and Microcrystalline Cellulose and sieve through appropriate sieve. 5.
  • Loading Add the intra-granular excipients in a high shear mixer granulator and load the active ingredient dispersion in molten liquid mixture of Lauroyl macrogol-32 glycerides from step 3 on the intra-granular excipients, and mix until a homogenized waxy mixture is obtained and allow granules to cool down.
  • Lubrication Weight individually Magnesium Stearate, sieve it through appropriate sieve and mix with the blend obtained from step 8 for appropriate time.
  • Compression Compress the homogeneous powder obtained from step 9 in tablets in a rotary tabletting machine using appropriate punches.
  • compositions of the present invention may optionally be prepared by fluid bed granulation process.
  • the immediate release pharmaceutical composition of the present invention comprising Tadalafil as an active ingredient has been compared to reference product Cialis® consisting of Tadalafil with the following excipients croscarmellose sodium, hydroxypropyl cellulose, hypromellose, iron oxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, talc, titanium dioxide, and triacetin.
  • compositions according to the present invention are characterized by excellent pharmacotechnical properties, such as homogeneity, flowability and compressibility. Thanks to these properties, the solid dosage forms prepared by the process according to the present invention exhibit excellent technical characteristics including dissolution rate, hardness, stability, taste and bioavailability.
  • Dissolution test One of the most critical pharmacotechnical tests is the Dissolution test as it is strongly correlated with the bioavailability of.the product.
  • a Paddle Apparatus was used at rotation speed 50rpm, in aqueous dissolution medium with 0.4%SLS.
  • composition 3 according to the present invention has enhanced dissolution rate in comparison to reference product, thereby providing an in vitro release of Tadalafil as depicted in Fig. 2.
  • Table 1 Comparative dissolution results of Composition 3 and reference product
  • composition 3 was exposed to normal and accelerated stability studies according to the current ICH guidelines.
  • the tablets may be chewable, film coated with functional or non-functional coating.
  • Example 1 Tadalafil composition 1 according to the present invention.
  • Composition 1 of the present invention is illustrated in TABLE 2 below.
  • Composition 1 comprises Tadalafil and Lauroyl macrogol-32 glycerides mixture as solubilizing agent, wherein the weight ratio of Tadalafil to Lauroyl macrogol-32 glycerides mixture is 1 : 1.
  • TABLE 2 Tadalafil composition 1
  • Chewable tablets of composition 1 of Example 1 were prepared according to the following manufacturing process:
  • Tadalafil as active pharmaceutical ingredient was weighted individually and passed through appropriate sieve.
  • Solubilizing agent Lauroyl macrogol-32 glycerides mixture was weighted individually and then, melted at temperature of about 75°C.
  • the sieved Tadalafil was added in the molten liquid of the solubilizing agent and mixed for appropriate time until fully dispersed.
  • the intra-granular excipients Lactose Monohydrate and Microcrystalline Cellulose as diluents were weighted, sieved, and transferred in a high shear mixer granulator.
  • the Tadalafil dispersion is loaded onto the intra-granular excipients and the obtained granules were left to cool down and then passed through an appropriate sieve.
  • the extra-granular excipients Hydroxypropyl Cellulose-SL as binder , Croscarmellose Sodium as disintegrant, colloidal silicon dioxide (AerosilTM 200) as glidant, Sodium Lauryl Sulfate as solubiliser, Aspartame as sweetener and Flavor Peppermint as flavor were weighted, sieved and mixed together with the granules obtained from the second stage for appropriate time until complete homogeneity.
  • Magnesium stearate as lubricant was weighted sieved and mixed with the mixture obtained from previous stage.
  • the resulting powder was compressed in tablets in a rotary tabletting machine using appropriate punches. The produced tablets were tested for hardness, friability, disintegration, and water content. All tests were performed according to European Pharmacopoeia 5.1 and were well within the specifications
  • Tadalafil composition 2 according to the present invention is illustrated in TABLE 3 below
  • Composition 2 comprises Tadalafil and Lauroyl macrogol-32 glycerides mixture as solubilizing agent, wherein the weight ratio of Tadalafil to Lauroyl macrogol-32 glycerides mixture is 1:2.
  • Chewable tablets of composition 2 of Example 2 according to the present invention were prepared according to the same manufacturing process as described in composition 1 of Example 1.
  • Tadalafil composition 3 according to the present invention is illustrated in TABLE 4 below.
  • Composition 3 comprises Tadalafil and Lauroyl macrogol-32 glycerides mixture as solubilizing agent, wherein the weight ratio of Tadalafil to Lauroyl macrogol-32 glycerides mixture is 1 :3.
  • Chewable tablets of composition 3 of Example 3 according to the present invention were prepared according to the same manufacturing process as described in composition 1 of Example 1.
  • composition 3a comprising Tadalafil and the same excipients as composition 3 of the present invention, however without non-ionic water dispersible surfactant, Lauroyl macrogol-32 glycerides mixture as solubilizing agent is prepared by using dry blending process instead of the application of solubilising agent on the active pharmaceutical ingredient and using melt granulation process.
  • the manufacturing process of composition 3a comprises the following steps: Weight individually the active ingredient (Tadalafil) and Microcrystalline Cellulose and pass them through the appropriate sieve. Mix Tadalafil and Microcrystalline Cellulose for appropriate time.
  • the obtained mixture is mixed with the following pre-lubrication blend excipients: Lactose Monohydrate, Hydroxypropyl Cellulose-SL, Sodium Lauryl Sulfate (SLS), Croscarmellose Sodium, Aspartame and Flavour Peppermint for appropriate time. Subsequently, the obtained blend is mixed with Magnesium Stearate for appropriate time and the final obtained homogeneous powder is compressed in tablets.
  • composition 3 of the present invention comprising a nonionic water dispersible surfactant as a solubilizing agent and composition 3 a comprising no solubilizing agent and prepared by dry blending process are shown in Fig. 1.
  • the results indicate that composition 3 of the present invention has a significantly higher drug release rate when compared with composition 3a when tested with the same dissolution method, which is also the Quality Control dissolution method, a method adequate to distinguish the good from bad composition. More than 90% of the drug of composition 3, is released within lOmin using a nonionic water dispersible surfactant as solubilizing agent while about 70% is released within 10 min of composition 3 a without any solubilizing agent and when a conventional process such as dry blending process is used.
  • composition 3 of the present invention was tested at several aqueous buffers and compared with the reference product. As it is shown in Fig. 2, composition 3 of the present invention has enhanced dissolution profile compared to the reference product when tested with the same dissolution method.
  • Example 4 Tadalafil composition 4 according to the present invention is illustrated in TABLE 5 below.
  • Composition 4 comprises Tadalafil and Lauroyl macrogol-32 glycerides mixture as solubilizing agent, wherein the weight ratio of Tadalafil to Lauroyl macrogol-32 glycerides mixture is 1 :5.
  • Chewable tablets of composition 4 of Example 4 according to the present invention were prepared according to the same manufacturing process described in composition 1 of Example 1.
  • compositions 1, 2, 3 and 4 of the present invention have been performed under the same conditions as in table 1.
  • TABLE 5 Comparative dissolution results of Compositions 1, 2, 3 and 4 of the present invention and reference product
  • the dissolution profiles of the compositions 3 and 4 of the present invention in table 5 indicate that Tadalafil solid dosage formulation prepared with solubilizing excipient Lauroyl macrogol- 32 glycerides mixture and melt granulation process are enhanced than the dissolution profile of reference product.
  • Lauroyl macrogol-32 glycerides mixture as a dissolution enhancing agent in combination with the melt granulation process, facilitates the drug release and increases the bioavailability of the active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique améliorée comprenant une quantité thérapeutiquement efficace de tadalafil ou d'un sel ou dérivé pharmaceutiquement acceptable de celui-ci, en tant que principe actif et une quantité efficace de tensioactif dispersible dans l'eau non ionique en tant qu'agent améliorant la solubilisation pour augmenter efficacement la libération de médicament, la solubilité aqueuse et la biodisponibilité orale.
PCT/EP2022/000051 2022-06-02 2022-06-02 Composition pharmaceutique améliorée contenant du tadalafil et son procédé de préparation WO2023232215A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2022/000051 WO2023232215A1 (fr) 2022-06-02 2022-06-02 Composition pharmaceutique améliorée contenant du tadalafil et son procédé de préparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2022/000051 WO2023232215A1 (fr) 2022-06-02 2022-06-02 Composition pharmaceutique améliorée contenant du tadalafil et son procédé de préparation

Publications (1)

Publication Number Publication Date
WO2023232215A1 true WO2023232215A1 (fr) 2023-12-07

Family

ID=82483243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/000051 WO2023232215A1 (fr) 2022-06-02 2022-06-02 Composition pharmaceutique améliorée contenant du tadalafil et son procédé de préparation

Country Status (1)

Country Link
WO (1) WO2023232215A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033239A2 (fr) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Formulations nanoparticulaires de tadalafil
WO2011135426A1 (fr) * 2010-04-26 2011-11-03 Intelgenx Corp. Formes dosifiées orales solides contenant du tadalafil
WO2014167579A2 (fr) * 2013-03-28 2014-10-16 Astron Research Limited Compositions pharmaceutiques stables de tadalafil
CN107303284A (zh) * 2016-04-25 2017-10-31 湖北生物医药产业技术研究院有限公司 制备他达拉非片剂的方法及他达拉非片剂
CN110812336A (zh) * 2018-08-07 2020-02-21 迪沙药业集团（天津）药物研究有限公司 一种他达拉非片剂组合物
CN113855639A (zh) * 2021-11-04 2021-12-31 昆明源瑞制药有限公司 一种他达拉非片剂及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033239A2 (fr) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Formulations nanoparticulaires de tadalafil
WO2011135426A1 (fr) * 2010-04-26 2011-11-03 Intelgenx Corp. Formes dosifiées orales solides contenant du tadalafil
WO2014167579A2 (fr) * 2013-03-28 2014-10-16 Astron Research Limited Compositions pharmaceutiques stables de tadalafil
CN107303284A (zh) * 2016-04-25 2017-10-31 湖北生物医药产业技术研究院有限公司 制备他达拉非片剂的方法及他达拉非片剂
CN110812336A (zh) * 2018-08-07 2020-02-21 迪沙药业集团（天津）药物研究有限公司 一种他达拉非片剂组合物
CN113855639A (zh) * 2021-11-04 2021-12-31 昆明源瑞制药有限公司 一种他达拉非片剂及其制备方法

Similar Documents

Publication Publication Date Title
TWI763881B (zh) 帕博西里之固態劑型
RU2456989C2 (ru) Твердые лекарственные формы, содержащие тадалафил
EP2331074B1 (fr) Granulés, leur procédé de préparation et produits pharmaceutiques les contenant
EP2180883B1 (fr) Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation
JP2023011873A (ja) 医薬組成物
CA2703313C (fr) Formes galeniques orales renfermant de l'acetate de licarbazepine
EP1849830B1 (fr) Composition finement divisee contenant un substance peu hydrosoluble
JP2008531509A (ja) 医薬品成分の改良された分散性を有する錠剤
CA2599649C (fr) Formulations medicamenteuses ayant une biodisponibilite controlee
JP2012509320A (ja) テノフォビル、エムトリシタビン及びエファビレンツの湿式造粒法
JP2010536798A (ja) 難溶性薬物の生体利用率を制御するための方法及び組成物
US20100003319A1 (en) Raloxifene immediate release tablets
WO2023232215A1 (fr) Composition pharmaceutique améliorée contenant du tadalafil et son procédé de préparation
EP1773300B1 (fr) Composition pharmaceutique solide comprenant de la mirtazapine
EP4531815A1 (fr) Composition pharmaceutique améliorée contenant du tadalafil et procédé de nanobroyage pour sa préparation
JP2019065006A (ja) 生産性及び均一性が改善されたタダラフィルを含む固形製剤、及びその製造方法
WO2022042646A1 (fr) Composition de chlorhydrate de lurasidone et son procédé de préparation
US20250000839A1 (en) Pharmaceutical composition comprising enavogliflozin
WO2024136769A1 (fr) Compositions de comprimés divisibles de manière homogène comprenant de l'acide carglumique
WO2024136768A1 (fr) Compositions pharmaceutiques stables contenant du tolvaptan amorphe
WO2023126973A1 (fr) Composition pharmaceutique stable d'elagolix
KR20250048897A (ko) 용해도 및 안정성이 개선된 팔보시클립을 포함하는 약학 조성물
CN119365195A (zh) 含有匹米替比的医药组合物
WO2014157603A1 (fr) Composition pharmaceutique pour administration orale
CA2709624A1 (fr) Forme posologique a liberation immediate de bosentan et procede de fabrication de ladite forme posologique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22740290

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE